IL6 and congenital rubella syndrome: Tocilizumab was administrated in 33 patients including 17 patients with grade 1, 9 patients with grade 2, 5 patients with grade 3–5 CRS, and one patient with headache and elevated IL-6 in peripheral blood and cerebrospinal fluid instead of symptoms of CRS.